Purpose: Patients with colorectal cancers (CRC) and high microsatellite instability (MSI) have a better outcome than their chromosome-unstable counterpart. Given the heterogeneity of microsatellite-unstable CRCs, we wanted to see whether any MSI-associated molecular features are specifically associated with prognosis.
Introduction
Several proteins participate in the task of the DNA mismatch repair (MMR) system, which is to correct base substitution mismatches and insertion-deletion mispairs generated during DNA replication. These proteins need to dimerize to form MutS and MutL functional complexes which bind to mismatches. Heterodimerization of MSH2 with MSH6 or MSH3 forms MutSa and MutSb, whereas heterodimers of MLH1 with PMS2, hPMS1, or hMLH3 produce MutL. MutSa recognizes single base-base and insertion-deletion loops of 1 or 2 nucleotides, MutSb preferentially recognizes larger mismatches, and MutL acts as a molecular matchmaker (1) .
About 15% of colorectal cancers (CRC) are caused by MMR gene defects (2, 3) . MMR dysfunction leads to cancer development through the accumulation of unrepaired frameshift mutations in simple repeat sequences, called microsatellites, of target genes involved in cell growth regulation (4) . In fact, widespread high microsatellite instability (MSI) is the hallmark of this carcinogenetic pathway also referred to as the "mutator" pathway. MSI can arise from germ line mutations in MSH2 (5, 6) and MLH1 (7, 8) , less frequently in PMS2 (9) and in MSH6 (10) genes, which determine Lynch syndrome. Alternatively, microsatelliteunstable cancers may originate from epigenetic silencing of MLH1, which accounts for the vast majority of MSI sporadic CRCs (11, 12) . In addition to the primary MMR defect, secondary losses of MMR protein can occur as a consequence of MSH3 and MSH6 frameshift mutations promoted by MLH1 inactivation (13) (14) (15) or because of MSH3 and MSH6 protein degradation in cancers not expressing the heterodimeric partner MSH2 (16, 17) . As a result, single or combined defects of MMR subunits (MutL, MutSa, and MutSb) can variably underlie the genetic instability of microsatellite-unstable CRCs.
Microsatellite-unstable CRCs have a better prognosis than microsatellite-stable tumors (18, 19) . Downstaging at diagnosis, that is, a lower prevalence of metastatic disease, accounts for the prognostic advantage of these cancers (20) . The dense immune infiltrate and the high number of recovered negative lymph nodes (21, 22) , possibly reflecting the enhanced immunogenicity of frameshifted peptides (23, 24) , might help interpreting the reduced metastatic potential of microsatellite-unstable CRCs. However, the molecular basis for the prognostic advantage of microsatellite-unstable cancers has not been clearly established. In particular, it is not known whether a correlation exists between the metastatic potential of microsatellite-unstable tumors and primary or secondary MMR defects associated with genetic instability. Aim of this article was to see whether distinct patterns of MMR protein expression in the primary tumor can identify subsets of microsatelliteunstable cancers with different invasiveness and prognosis.
Materials and Methods

Pathologic assessment of microsatellite-unstable CRCs
Systematic molecular screening for MSI was conducted on 1,041 CRC consecutively resected from Caucasian patients at the Istituto Clinico Humanitas (Milan, Italy), between January 1, 1997, and June 18, 2006. DNA was purified by standard procedures from paraffin sections of formalin-fixed tissue with a neoplastic cell content above 50%. BAT26 and BAT25 loci were amplified by fluoresceinated primers, and PCR products analyzed by capillary electrophoresis (ABI PRISM 310 DNA Sequence; PE Applied Biosystems). The MSI phenotype (high-MSI) was defined by the appearance of shorter alleles at BAT26 and/or at BAT25 (25) .
One hundred and nine patients with microsatelliteunstable CRCs were identified. Following approval of the study by the local Ethical Committee, the informed consent of patients to treatment of their personal data was obtained by the referring physician or by other clinicians involved in the study. Demographics and complete clinical data at diagnosis were made available at hospital intranet resources. An accurate family history, aimed at recognizing the Amsterdam clinical criteria (AC II) for hereditary nonpolyposis colorectal cancer (HNPCC; ref. 26) , was obtained from all patients.
Densities of CD3 þ cells (CD3 þ TIL IM ) were assessed by immunostaining of tissue sections followed by a computerassisted measurement of the percent areas of CD3þ tumorinfiltrating lymphocytes (TIL) immunoreactivity at the invasive margin of the tumor (TIL IM ), as previously described (27) . An average of 25 AE 12 lymph nodes (mean þ SD) were made available for assessing nodal status. The node negative count was inferior to 12 in 7 (6.4%) cases (11, 11, 10, 10, 9, 6 , and 4 nodes, respectively). Tumor clinicopathologic staging by American Joint Committee on Cancer (28) was assessed by combining histopathologic findings with surgical records and perioperative imaging (20) Molecular subtyping of microsatellite-unstable CRC Primary MMR defect. Each microsatellite-unstable CRC was tested by immunohistochemistry for nuclear expression of MLH1 (G-168 monoclonal antibody, PharMingen), MSH2 (clone FE 11, Oncogene Sciences), MSH6 (clone 44, Transduction Laboratories), and PMS2 (clone A16-4, PharMingen; refs. 29, 30) .
All patients with MLH1-or MSH2-deficient CRCs underwent sequencing of the corresponding gene (30) . Mutationnegative patients were further tested by multiplex ligationdependent probe amplification (MLPA kit, MRC-Holland), which detected deletions within the MSH2 gene in 3 cases.
Secondary loss of MSH3 and/or MSH6. The expression of MSH3 (clone 52/MSH3, monoclonal antibody, Transduction Laboratories) and MSH6 protein was also evaluated by immunohistochemistry in the entire series of microsatelliteunstable CRCs. Staining was visualized by the Avidin-Biotin Method (Vectastain, Vectro Laboratories).
Microsatellite-unstable cancer cell lines were also characterized for MMR protein expression by Western blotting. Membranes from SW48, LS174T, HCT116, and DU145 cancer cells were incubated for 1 hour with TBS and 5% skimmed milk, then overnight with primary antibodies directed against MMR protein, finally for 1 hour with anti-mouse or anti-rabbit secondary antibody conjugated to horseradish peroxidase (Amersham. GE Healthcare BioSciences Corp.), and visualized by the Amersham Enhanced Chemiluminescent Detection System. To assess the association with secondary MMR protein loss, the presence of frameshift mutations at the (A) 8 repeat of exon 7 of MSH3 and at the (C) 8 repeat of exon 5 of MSH6 was tested in DNA
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extracted from each cell line and from areas of MLH1-deficient tumors that had been microdissected under the guidance of immunostaining.
Frameshift mutations at mutator or target genes. Frameshift mutations at coding mononucleotide repeats within MSH3, MSH6, TGFBR2, BAX, TCF4, CASP5, MBD4, AXIN2, and ACVR2A genes were investigated. PCRs were carried out with fluoresceinated specific primers and products were analyzed for the presence of mutant alleles differing by at least AE1 bp, according to previously described methods (31) .
RAS pathway mutations. Mutations at KRAS and BRAF hot spots were detected by PCR-RFLP. KRAS codon 12 and 13 mutations were, respectively, detected by a modified primer that creates a restriction site for BstNI and XcmI (New England Biolabs Inc.) restriction enzymes (32) . BRAF c.1799T>A mutations were analyzed by exon 15 amplification followed by digestion with TspRI (New England Biolabs) restriction enzyme (33) .
MLH1/CDKN2A promoter hypermethylation. The DNA methylation status of MLH1 and CDKN2A promoters was determined by methylation-sensitive PCR based upon DNA treatment with sodium bisulfite and amplification with primers specific for methylated and unmethylated DNA (34).
Follow-up of patients
The observation period started immediately after surgery (mean AE SD, 4.7 AE 2.8 years), and the survival was calculated from diagnosis until tumor recurrence, or until data were censored, as of July 1, 2011. Thoracoabdominal computed tomography (1.2 AE 0.5 per patient per year, mean AE SD), abdominal ultrasonography (1.7 AE 0.5), and chest radiography (1.15 AE 0.4) were conducted according to common protocols for surveillance. Chemotherapy was always administered on clinical grounds and not in the context of prospective trials. 
Statistical analysis
Associations between molecular features of microsatellite-unstable cancers or between molecular and clinicopathologic features were tested by c 2 test for categorical variables and by unpaired Student t test for means of continuous variables. All pathologic and molecular factors significantly associated with nodal involvement were entered into a multivariate stepwise logistic regression analysis.
Survival curves were drawn according to the KaplanMeier method, and the proportions of events were compared by Fisher test.
Results
Frameshift mutations and variable expression of MSH3 and MSH6 protein in microsatellite-unstable cancer cell lines Figure 1 illustrates the correlation between genotype and protein expression for MSH3 and for MSH6 in microsatellite-unstable CRC cell lines. As MLH1-deficient cell lines were tested, the expression of MSH3 was equivalent to that of MMR-proficient cells (HeLa) in SW48 cells carrying no MSH3 mutation, greatly reduced in DU145 cells harboring a monoallelic MSH3 frameshift mutation, and abolished in HCT116 cells having a biallelic MSH3 truncating mutation. MSH6 was expressed in all cell lines, although the protein levels were reduced in LS174T, DU145, HCT116, and SW48 cells carrying a heterozygous MSH6 frameshift mutation. Both MSH3 and MSH6 proteins were undetectable in the MSH2-deficient LoVo cell line. showed lower levels of expression for both proteins, and HCT116 (À1 bp biallelic MSH3 mutation and monoallelic MSH6 mutation) failed to express MSH3. Dotted line indicates the peak of wild-type alleles.
Single or combined MMR defect(s) in 109 consecutive microsatellite-unstable CRCs Immunohistochemistry recognized lack of MLH1 (n ¼ 84; 77.1%), MSH2 (n ¼ 22; 20.2%), or MSH6 (n ¼ 3; 2.7%) as the primary MMR defect. No primary PMS2 defect was detected.
Germ line predisposing defects were identified in 26 patients (14 with MSH2 and 12 with MLH1 mutation) with Lynch syndrome. Amsterdam II criteria were fulfilled in 24 (22%) patients, 8 of whom had no detectable MLH1 or MSH2 germ line mutation.
All MSH2-deficient cancers failed to express both MSH3 and MSH6 protein. DNA analysis of microdissected areas of MLH1 cancers confirmed a strong correlation between MSH3 genotype and protein expression (Supplementary Material S1). Of 40 neoplastic areas not expressing MSH3 (31 from cancers with homogeneous protein loss and 9 from tumors with only focal MSH3 loss), 31 (78%) harbored 2 (A) 7 mutated alleles, 9 (22%) had a heterozygous frameshift, and none had both wild-type alleles. About 30% of cancers still expressing the MSH3 protein harbored a heterozygous frameshift mutation within the (A) 8 repeat. Homozygous mutations of MSH6 were also limited to cancers not expressing the protein, but biallelic frameshift mutations accounted for loss of MSH6 only in 2 of 11 (18%) cancers. The overall frequency of MSH6 hetero-or homozygous frameshift in MLH1-deficient CRCs (17 of 84, 20.2%) was significantly lower (P < 0.001) than that of MSH3 mutations (46 of 84, 54.8%). Figure 3 shows the frequency of mutations at 7 well recognized "targets" of DNA repeat instability (cell growth/survival genes), in microsatellite-unstable CRC subsets defined by MMR protein defect. The primary MMR defect was first considered (A). Two of 3 MSH6-deficient CRCs had no mutation in the investigated genes and the third exhibited only a frameshift in MBD4. The mutational rate in MSH6-deficient CRCs was significantly lower (P < 0.01) than that observed both in MLH1-and MSH2-deficient tumors. The number (mean AE SD) of mutated targets was higher, although not significantly (P ¼ 0. The number of target genes with frameshift mutation was higher in MSH2-deficient cancers (3.95 AE 1.8) than in MLH1-deficient tumors with no secondary loss (2.95 AE 1.8; P ¼ 0.04) or with MSH6 loss (2.78 AE 1.69; P ¼ 0.09), but almost identical to that observed in MLH1-deficient tumors with secondary MSH3 loss (3.94 AE 1.9; P ¼ 0.96).
Mutations in target genes
Mutations in genes of the KRAS pathway
KRAS codons 12 to 13 mutations more frequently occurred in cancers whose primary MMR defect was MSH2 (10 of Methylation of MLH1 and CDKN2A promoter MLH1 promoter methylation was significantly more frequent in MLH1-deficient CRCs (66 of 84, 78.6%) than in MSH2-(6 of 22, 27.3%; P < 0.001) and MSH6 (0 of 3; P ¼ 0.002)-deficient tumors. In sporadic MLH1-deficient cancers, the methylation rate of MLH1 promoter was higher than in MLH1-deficient cancers from patients with hereditary cancer (sporadic, 60 of 70, 85.7%; hereditary, 6 of 14, 42.9%; P ¼ 0.001) The rate of CDKN2A methylation was higher, although not significantly, in MLH1-deficient CRCs (47 of 84, 56.0%) than in MSH2-(8 of 22, 36.4%; P ¼ 0.10) and in MSH6-deficient tumors (1 of 3, 33%) .
Twenty-three of 31 (74.2%) MLH1-deficient tumors with secondary MSH3 loss, 7 of 9 (77.8%) cancers with secondary MSH6 loss, and 36 of 44 (81.8%) tumors with no secondary MMR protein loss exhibited MLH1 methylation. The methylation rate of CDKN2A in MLH1-deficient CRCs was also unaffected by secondary protein loss (MSH3 loss: 18 of 31, 58.1%; MSH6 loss: 6 of 9, 66.7%; no additional loss: 23 of 44, 52.3%). Table 1 details patient characteristics and tumor pathologic features according to tumor MMR defects. As to the primary MMR defect, MSH2-deficient tumors were diagnosed at younger age than MLH1-deficient CRCs (P ¼ 0.001), had a higher likelihood to be HNPCCs (P ¼ 0.001), included a larger subset of left-sided cancers (P ¼ 0.03), and had a lower degree of local invasion (P ¼ 0.03). Two of 3 MSH6-deficient cancers had evidence of distant organ metastasis at diagnosis (P < 0.001 vs. MSH2-and MLH1-deficient tumors, despite the very small numbers). MLH1-deficient cancers were then classified by the occurrence of secondary MMR protein deficiency. To this aim, tumors with only focal areas of MSH3 deficiency (n ¼ 9) were considered as MSH3 still expressing tumors. Cancers with additional loss of MSH3 had a rate of nodal involvement significantly lower than that of CRCs with no secondary loss (P < 0.001) or with additional loss of MSH6 (P ¼ 0.02) and were diagnosed at an earlier stage than the remaining MLH1-deficient tumors (P ¼ 0.01). Notably, the node-negative count in cancers with MSH3 loss (24.1 AE 10.8) was not different (P ¼ 0.34) from that of cancers retaining MSH3 protein expression (21.6 AE 11.3). MLH1-deficient cancers with no loss (P ¼ 0.05), but not those with . , cumulative number of target genes with a frameshift (of 7; mean AE SD).^, TGFBR2; D, CASP5; *, BAX; , MBD4; , TCF4; , AXIN; &, ACVR2A. A, top, the 3 MSH6-deficient cancers had an overall number of mutated target genes significantly lower than that of MSH2-and MLH1-deficient tumors. Bottom, only a frameshift at MBD4 was detected in 3 MSH6-deficient cancers. TCF4 frameshift mutations were more frequent in MSH2-deficient cancers than in MLH1-deficient tumors (P < 0.001, bold). B, top, MLH1-deficient cancers with secondary MSH3 loss had a number of mutated genes significantly higher than tumors with no additional MMR loss or with secondary loss of MSH6. The number of target genes with frameshift mutation in MSH2-deficient cancers was also significantly higher than that observed in with no secondary loss (P ¼ 0.04) but not different from that seen in MLH1-deficient tumors with MSH3 loss. Bottom, CASP5 frameshift mutations were more frequent in MLH1-and MSH3-deficient cancers than in MLH1-only-deficient tumors (P ¼ 0.001, bold). Associations between nodal involvement and pathologic or molecular features of 84 MLH1-deficient CRC are shown in Table 2 . At univariate analysis, a positive association was seen for local invasiveness (pT3-pT4 vs. pT1-pT2, P < 0.007), grade (III vs. I-II, P < 0.001), and histotype (mucinous/medullary vs. adenocarcinoma, P < 0.001), whereas a negative correlation was observed for MSH3 loss (P < 0.001), frameshift mutations at MSH3 (P ¼ 0.02 vs. wildtype), and !3 mutated MSI target genes (P ¼ 0.01). At multivariate, however, only MSH3 loss (P < 0.001) and grading (P ¼ 0.001) were independently associated with nodal status. MSH3 loss remained associated with absence of nodal metastasis if cancers with MSH3 focal loss were excluded (OR, 0.13; 95% CI, 0.04-0.45; P ¼ 0.001), and even if they were grouped with MSH3-deficient tumors (OR, 0.26; 95% CI, 0.10-0.68; P ¼ 0.006). The rate of nodal involvement in MSH3-negative tumors was significantly lower than that of MSH3-positive cancers both in BRAF wild-type cancers (2 of 14 vs. 16 of 30; OR, 0.15; 95% CI, 0.02-0.74; P ¼ 0.01) and in the BRAF-mutated subgroup (2 of 17 vs. 12 of 23; OR, 0.12; 95% CI, 0.02-0.64; P ¼ 0.009).
Clinicopathologic features at time of diagnosis
Nodal status resulted to be independently associated with MSH3 loss (OR, 0.19; 95% CI, 0.07-0.48; P < 0.001) and with grading (OR, 6.13; 95% CI, 2.42-15.5, P < 0.001) also if the multivariate analysis was applied to the entire series of 109 microsatellite-unstable CRCs including MSH2-deficient cancers (Supplementary Material S2).
Patient survival
In our series of microsatellite-unstable CRCs (MLH1-or MSH2-deficient cancers), none of the 10 patients with stage I CRC but 10 of 67 (14.9%) patients with stage II/III cancer were diagnosed with postsurgical local recurrence or metachronous metastasis (mean postsurgical follow-up, 5.65 AE 2.8 years). Figure 4 shows the disease-free survival curves from patients undergoing colonic resection for stage II/III microsatellite-unstable CRC, classified by primary MMR defect and by MSH3 expression. As a reference, the survival of patients with stage II/III pT3/pT4 microsatellite-stable (MSS) CRCs is also shown. Among patients with MLH1-deficient cancers, those with MSH3-negative tumors had a better disease-free survival (P ¼ 0.06 by Fisher test), and their survival curve was almost similar to that of patients with primary MSH2 defect. The higher prevalence of stage II CRC (21 of 24, in MSH3-deficient tumors vs. 20 of 43, in MSH3-expressing cancers; P < 0.001) accounted for the better survival of patients with MSH3-deficient cancers. As the survival of patients with MLH1-deficient tumor was compared with that of patients with stage II/III MSS CRCs, a significant difference was observed for MSH3-negative cancers (P ¼ 0.007) but not for MSH3-negatives ones (P ¼ 0.28).
Among patients with MLH1-deficient CRCs, the diseasefree survival of patients with BRAF-mutated cancer was not different from that of patients with BRAF wild-type tumor (Supplementary Material S3).
Association between MSH3 loss and nodal status in an independent series
Of 71 additional MLH1-deficient cancers resected at other institutions, 20 (28.2%) did not express MSH3 and 11 (15.5%) showed heterogeneous expression of MSH3. The fraction of cancers lacking MSH3 protein was not significantly different from that of our institutional series (20 of 71 vs. 31 of 84, P ¼ 0.25), neither was different the rate of MSH3 loss in hereditary (8 of 25, 32%) or sporadic cancers (12 of 45, 26.7%; P ¼ 0.78). The analysis of the (A) 8 mononucleotide repeat in the exon 7 of MSH3 confirmed the strong correlation between the presence of frameshift mutation and the loss of MSH3 protein. Of 20 cancers not expressing MSH3, 15 (75.0%) harbored MSH3 homozygous frameshift mutation (A) 7 , 5 (25.0%) showed heterozygous frameshift mutation, and none had both wild-type alleles. Of 51 cancers expressing MSH3, 14 (27.5%) harbored a heterozygous frameshift mutation within the repeat and the remaining 37 (72.5%) cancers showed both wildtype alleles. Also in this series, tumors with additional loss of MSH3 had a rate of nodal involvement (4 of 20, 20.0%) significantly lower than that of cancers with no secondary loss (25 of 51, 49.0%; P ¼ 0.02). The association of nodal involvement with tumor features is detailed in Supplementary Material S3. Again, at multivariate analysis, MSH3 loss was negatively associated with nodal involvement (OR, 0.23; 95% CI, 0.06-0.81; P ¼ 0.02; Supplementary Material S4). As data from our monoinstitutional series and those from the independent series of hMLH1-deficient CRCs were pooled, a highly significant association between secondary MSH3 loss and rate of nodal involvement was confirmed (OR, 0.16; 95% CI, 0.07-0.39; P < 0.001).
Discussion
The prognostic advantage of microsatellite-unstable CRCs over MSS cancers essentially reflects the earlier stages of these tumors, that is, the lower rate of lymph node and distant organ metastasis at time of diagnosis (20) . This concept is strongly supported by the fact that (35, 36) . The present study is the first to show that the outcome of microsatelliteunstable cancers varies according to different patterns of MMR defect, and, in particular, that the secondary loss of MSH3 protein identifies h-MLH1-deficient tumors at very low risk of nodal involvement and postsurgical recurrence. Given the overall better prognosis of microsatelliteunstable CRCs, the identification of a subclass with better outcome is particularly significant, as it might have been easily overlooked. It is also noteworthy that the association between tumor downstaging and MSH3 loss was confirmed in an independent validation series of microsatellite-unstable CRCs.
Microsatellite-unstable CRCs can undergo secondary loss of MMR protein through different mechanisms. Primary MSH2 deficiency invariably determines proteolytic degradation of both MSH3 and MSH6 (37), whereas MLH1-deficient cancers may become unable to express MSH3 and MSH6 in the course of tumor progression. Loss of MSH3 follows biallelic frameshift mutation at the (A) 8 coding mononucleotide repeat in exon 7 of MSH3, as observed in HCT116 cells (refs. 15, 38; Fig. 1 ). Of other molecular events possibly underlying MSH3 loss in MLH1-deficient CRCs, loss of heterozygosity typically occurs only in MSS tumors (39, 40) whereas gene promoter methylation has not been investigated. Having detected MSH3 biallelic frameshift mutations in about 80% of microdissected areas of MLH1-deficient cancers with MSH3 loss, we can assume Stepwise logistic regression; an OR < 1.00 represents a decreased likelihood of metastases whereas an OR > 1.00 represents an increased likelihood of metastases. The model was obtained by rejection of nonsignificant (P > 0.05) variables.
homozygous mutation as the key mechanism for MSH3 loss in such tumors (38) and even speculate that the detection of heterozygous-only frameshift mutations in a few MSH3-negative CRC might simply reflect an imperfect microdissection of cancer cells. Accordingly, we judge it unlikely that nongenetic changes have substantially contributed to MSH3 protein loss in our series. Differently from MSH3 loss, biallelic frameshift mutations at the mononucleotide repeat did not account for the secondary loss of MSH6 occasionally detected in MLH1-deficient CRCs and, in this case, a substantial role for somatic missense mutations (15) and single-base substitutions (14) has to be postulated. MSH3 expression resulted to be negatively associated with nodal involvement when the analysis was limited to MLH1-deficient cancers, but also when all microsatelliteunstable CRCs, including MSH2-deficient tumors, were considered. The association might be mediated by a lower degree of tumor local invasion (pT) in MSH2-deficient cancers, but not in MLH1-deficient tumors whose pT was not significantly influenced by the MSH3 status. Thus, loss of MSH3 in MLH1-deficient tumors, although delayed since cancer initiation, has to occur early enough to precede the spread of the tumor to regional lymph nodes. This is in accordance with the model of progression originally proposed for microsatellite-unstable CRCs by Duval and colleagues who found that MSH3 frameshift mutations were secondary only to TGFb mutations as early genetic events able to increase the global instability phenotype (41) . Our results are also in agreement with the inverse relationship between clinicopathologic staging and accumulation of frameshift mutations observed in a large series of sporadic microsatelliteunstable cancers (42) . In contrast, others (43) found an association between MSH3 loss and advanced tumor stage in a small group of MLH1-deficient CRCs, but the high rate of loss of heterozygosity suggests that that series was somehow enriched with tumors with overlapping patterns of microsatellite and chromosomal instability.
Different hypotheses have been made to explain the more indolent behavior of microsatellite-unstable CRCs. As compared with MSS cancers, microsatellite-unstable tumors might undergo a stronger antitumoral immune response induced by highly immunogenic truncated peptides (23, 24, 44) . Lymphocyte infiltrate being established as a favorable prognostic biomarker in CRCs (27, 45) , we found it particularly interesting that MSH3 frameshift mutations have been recently shown to act as antigenic epitopes of cytotoxic T cell (23) . However, the prognostic value of MSH3 loss in our series was independent of peritumoral densities of CD3 þ cells and there was no association between MSH3 frameshift mutations and lymphocytic infiltrate. Therefore, our result cannot support a role for immune response in the downstaging of MSH3-deficient tumors. Conversely, nodal involvement was negatively associated with the number of mutated target genes, supporting the alternative concept that genetic instability itself might, in fact, trigger a "self-limiting" program for the tumor by accumulating mutations even in genes necessary to cancer cell survival and progression (46) (47) (48) . Regardless of any possible clinical application for MSH3 loss as a prognostic biomarker, the analysis of disease-free survival strongly suggests a role for MSH3 in modulating the progression and the invasiveness of microsatellite-unstable CRCs. MutSb, resulting from heterodimerization of MSH2 with MSH3, and MutSa complex, formed by coupling of MSH2 with MSH6, are known to be partially redundant in the recognition of DNA mismatches. MutSa plays a predominant role for the recognition of base-base mismatches. Both complexes can detect small insertion-deletion loops up to 10 unpaired nucleotides (17, (49) (50) (51) , but MutSb exceeds affinity and efficiency of MutSa for loops made by 2 or more unpaired nucleotides (17, 49, 52) . We found that CRCs combining MutL and MutSb deficiency had a higher number of frameshift mutations at mononucleotide repeats of target genes than those carrying a simple loss of MutL. The correlation between the number of frameshift mutations at target genes and MSH3-negative tumors might simply reflect the greater likelihood for microsatellite-unstable CRCs with a higher mutational rate in target genes to acquire biallelic mutations at MSH3, and not vice versa. Therefore, caution must be exerted in interpreting the lower staging and the better outcome of cancers with MSH3 loss as the result of a more severe mutator phenotype, as protein loss or gene inactivation might directly affect tumor progression in the absence of any effect on MMR efficiency. Along this line, MSH3 deficiency has been recently shown to sensitize CRC cells to platinum drugs independently of any influence on the canonical MMR system (53) .
In summary, microsatellite-unstable CRCs lacking MSH3 expression have a lower rate of nodal involvement at diagnosis and a better outcome than other microsatelliteunstable tumors. This applies both to MSH2-deficient tumors, whose MSH3 loss is caused by protein degradation, and to MLH1-deficient cancers in which biallelic frameshift mutations at MSH3 can determine the protein loss. As a consequence, no prognostic advantage over MSS cancers should be taken as granted for MLH1-deficient tumors retaining MSH3 protein expression. The study has obvious statistical limitations due to the fact that each molecular subclass of microsatellite-unstable cancers represents only a very small fraction of a CRC series. Therefore, our results need to be validated in large additional series such as those of multicentric therapeutic trials in which tumor MSI assessment should be completed by MSH3 analysis.
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